21 research outputs found
Baseline characteristics and helminth infection at day -28.
<p>Baseline characteristics and helminth infection at day -28.</p
Antibody titers against the three vaccine strains at baseline (day 0), day 28 and day 84.
<p>Red lines indicate the mean of all volunteers of the antihelminthic treated group (AT) and blue lines indicate the mean of all participants of the placebo group. Dashed lines indicate antibody titers of each participant.</p
Study profile.
<p><sup>+</sup>Patients were excluded, because of infection with <i>S</i>. <i>haematobium</i>. *Participants not terminating the study are summarized as lost to follow up (n = 16).</p
Vaccine-specific IgG ASCs at day 0 and day 84, in antihelminthic treated (AT) and placebo group.
<p>Red and blue represent antihelminthic treated (AT) and control group.</p
Distribution of the worm burden in the two groups at day 0 and day 84.
<p>Distribution of the worm burden in the two groups at day 0 and day 84.</p
GMT of vaccine strain specific antibodies.
<p>GMT of vaccine strain specific antibodies.</p
Differences of HI titers between the respective visits (day 28, day 84) and day 0 (baseline).
<p>Red and blue colors represent the pre-treated (AT) and control group.</p
Vaccine specific IgA at day 0, day 28 and day 84 in antihelminthic treated (AT) (red) and placebo group (blue).
<p>Vaccine specific IgA at day 0, day 28 and day 84 in antihelminthic treated (AT) (red) and placebo group (blue).</p
Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV PsVNA50 in adults.
<p>Geometric mean titres, seropositivity rates, and proportions of seroresponders to rVSVΔG-ZEBOV-GP measured by ZEBOV PsVNA50 in adults.</p